News for Viking Therapeutics, Inc. (VKTX)

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.

Viking Therapeutics (VKTX) is set to take part in an upcoming meeting organized by B. Riley, which will be held in Montreal, Canada on June 18. This event provi

We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that Jim Cramer discusses. Back then, a humorous caller asked if they should “bulk up” on Viking Therapeutics, Inc. (NASDAQ:VKTX), referencing both […]

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.61, representing a +1.88% change from its previous close.

Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns, the easy gains of prior years have evaporated. While the average stock treads water, companies with genuine competitive advantages and exposure to secular growth themes are posting triple-digit gains.

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Market Analysis by covering: Summit Therapeutics PLC, TherapeuticsMD Inc, Viking Therapeutics Inc, Aclaris Therapeutics Inc. Read 's Market Analysis on Investing.com

Discover why Viking Therapeutics is gaining momentum as a high-risk, high-reward biotech play.

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out why VKTX stock is a strong buy.

Explore Viking's innovative GLP-1/GIP & THR-β therapies, with strong Phase 2/3 results, targeting major markets with tolerable, patient-friendly treatments.

Viking Therapeutics has a promising pipeline candidate in the fast-growing therapeutic area of weight loss. Madrigal Pharmaceuticals markets the only approved therapy for a disease whose prevalence is growing. Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns.

Axsome Therapeutics is taking off, led by a treatment for major depressive disorder. Iovance Biotherapeutics could transform how solid tumors are treated. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance Biotherapeutics (NASDAQ: IOVA), and Viking Therapeutics (NASDAQ: VKTX) are monster stocks in the making.

Viking Therapeutics (VKTX) is experiencing higher-than-normal options activity with a notable focus on bearish positions. A total of 5,462 put options have been

\n Viking Therapeutics (VKTX) shares surged 20% in the last month despite reporting increased net losses. Analysts predict a significant upside potential w

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Viking Therapeutics Inc (VKTX). The firm reduced its holding

Viking Therapeutics shares jumped following Pfizer's strategic announcement. Wall Street analysts project a significant upside for VKTX stock. Curren

Viking Therapeutics (VKTX) stock rises as Pfizer (PFE) plans to bolster its pipeline with cardiometabolic and other obesity drugs, through acquisitions. Read more here.

Key Takeaways: Viking Therapeutics (VKTX) posted a Q1 2025 net loss of $45.63 million, rising from last year's $27.36 million loss. Despite financial set